Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 10Breast Neoplasms 10Prostatic Neoplasms 9Neoplasms 7Hematopoietic and Lymphatic System Neoplasm 7Multiple Myeloma 3Lymphoma 3Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Malignant Solid Neoplasm 2Lung Neoplasms 2Leukemia 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hematopoietic and Lymphoid System Neoplasm 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Diseases 1Squamous Cell Carcinoma of Head and Neck 1Spondylitis, Ankylosing 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Psoriasis 1Prostate Cancer Patients 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

pembrolizumab 25Cisplatin 17Carboplatin 13Radiotherapy 12Cetuximab 9Blood Specimen Collection 9Docetaxel 8Paclitaxel 7Fluorouracil 7Drug Therapy 7toripalimab 6tislelizumab 4nimotuzumab 4atezolizumab 4Surveys and Questionnaires 4Radiation 4Chemoradiotherapy 4fludarabine 3Surgical Procedures, Operative 3Standard of Care 3Radiotherapy, Intensity-Modulated 3Cyclophosphamide 3Biopsy 3130-nm albumin-bound paclitaxel 3cemiplimab 2avelumab 2X-Rays 2Tocopherols 2Tiragolumab 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Head and Neck Neoplasms × Interviews as Topic × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡